<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7332875\results\search\drug\results.xml">
  <result pre="the three drugs through molecular dynamics simulation studies for 50â€‰ns." exact="Zidovudine" post="shows a very stable interaction with fluctuation starting at"/>
  <result pre="0 0.00 Disallowed regions 0 0.00 The end residues (excluding" exact="Glycine" post="and Proline) 8 Â Proline 64 Â Glycine 40"/>
  <result pre="0.00 The end residues (excluding Glycine and Proline) 8 Â" exact="Proline" post="64 Â Glycine 40 Â Total number of residues"/>
  <result pre="residues (excluding Glycine and Proline) 8 Â Proline 64 Â" exact="Glycine" post="40 Â Total number of residues 499 100 This"/>
  <result pre="PubChem databases and their docking score on each sites are" exact="Zidovudine" post="(âˆ’11.08, âˆ’9.09, âˆ’9.75), Valganciclovir (âˆ’8.102, âˆ’5.40, âˆ’8.30) and Ribavirin"/>
  <result pre="docking score on each sites are Zidovudine (âˆ’11.08, âˆ’9.09, âˆ’9.75)," exact="Valganciclovir" post="(âˆ’8.102, âˆ’5.40, âˆ’8.30) and Ribavirin (âˆ’8.59, âˆ’6.38, âˆ’7.94). Further"/>
  <result pre="are Zidovudine (âˆ’11.08, âˆ’9.09, âˆ’9.75), Valganciclovir (âˆ’8.102, âˆ’5.40, âˆ’8.30) and" exact="Ribavirin" post="(âˆ’8.59, âˆ’6.38, âˆ’7.94). Further ranking of these molecules was"/>
  <result pre="on each sites (Site 1, Site 2, Site 3) are" exact="Zidovudine" post="(âˆ’23.50, âˆ’16.37, âˆ’44.64), Valganciclovir (âˆ’49.88, âˆ’39.44, âˆ’48.05) and Ribavirin"/>
  <result pre="1, Site 2, Site 3) are Zidovudine (âˆ’23.50, âˆ’16.37, âˆ’44.64)," exact="Valganciclovir" post="(âˆ’49.88, âˆ’39.44, âˆ’48.05) and Ribavirin (âˆ’40.92, âˆ’47.82, âˆ’44.96) (Table"/>
  <result pre="are Zidovudine (âˆ’23.50, âˆ’16.37, âˆ’44.64), Valganciclovir (âˆ’49.88, âˆ’39.44, âˆ’48.05) and" exact="Ribavirin" post="(âˆ’40.92, âˆ’47.82, âˆ’44.96) (Table 6). Further ranking of these"/>
  <result pre="of drug molecules PubChem Id Indication Mechanism of action 1" exact="Zidovudine" post="72187 Antiviral drug used for the treatment of human"/>
  <result pre="activity against Human Immunodeficiency Virus Type 1 (HIV-1) (https://www.drugbank.ca/drugs/DB00495) 2" exact="Valganciclovir" post="135413534 Antiviral drug used for the treatment of cytomegalovirus"/>
  <result pre="incorporation with viral DNA&amp;amp; inhibits viral DNA polymerases (https://www.drugbank.ca/drugs/DB01610) 3" exact="Ribavirin" post="37542 Used for the treatment of chronic Hepatitis C"/>
  <result pre="water bridges (Figure 6(B)). Figure 5(C) shows the interaction of" exact="Zidovudine" post="with the target protein. It shows a very stable"/>
  <result pre="The RMSF fluctuation is also very low in case of" exact="Zidovudine" post="(0.8 minimum to 4.3) as compared to two other"/>
  <result pre="has been used in one earlier study that has shown" exact="theophylline" post="and pyrimidine groups of drugs as promisable interactions (Sarma"/>
  <result pre="have antiviral activities and drugs from PubChem databases are Zidovudine," exact="Valganciclovir" post="and Ribavirin. Thus, anti-HIV drugs as well as anti-Herpes"/>
  <result pre="MD simulation to find final three drugs. Out of those," exact="Zidovudine" post="has stronger and more stable interaction with this protein"/>
  <result pre="stable interaction with this protein structure. Therefore, the drugs especially" exact="Zidovudine" post="can be further explored in the clinical trial as"/>
 </snippets>
</snippetsTree>
